Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Core Insights - Anavex Life Sciences Corp. has successfully completed enrollment for its Phase 2 clinical study of ANAVEX3-71, targeting schizophrenia, with a total of 71 participants [2][3][4] - The study consists of two parts: Part A with 16 participants focusing on multiple ascending doses, and Part B with 55 participants aimed at providing comprehensive clinical and biomarker data [3][4] - Top-line data from the study is expected to be reported in the second half of 2025 [5] Company Overview - Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company focused on developing treatments for various CNS disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia [2][7] - The lead drug candidate, ANAVEX2-73, has shown promise in multiple clinical trials for Alzheimer's disease and other CNS disorders [7][8] - ANAVEX3-71 is a dual SIGMAR1 receptor agonist and M1 positive allosteric modulator, which may address all symptom domains of schizophrenia without the side effects associated with standard antipsychotics [4][8] Industry Context - Schizophrenia affects nearly 24 million people globally, with significant unmet medical needs due to limitations of current treatments [6] - Approximately 34% of individuals with schizophrenia do not respond to existing therapies, and 50-60% experience only partial improvement or unacceptable side effects [6]